Fluorescent spectroscopic sensor technology for endotoxin detection in aqueous solutions

Overview

This technology offers a novel approach to detecting and quantifying bacterial endotoxin in aqueous samples using engineered fluorescent biosensors. Endotoxin, a toxic component of Gram-negative bacterial outer membranes, is a critical contaminant of concern in pharmaceutical manufacturing, clinical diagnostics, water safety, and biomedical research. Current detection methods, such as the Limulus Amebocyte Lysate (LAL) assay, rely on biological reagents with limitations in cost, speed, and supply chain reliability. This platform provides a reagent-free, protein-engineering-based alternative that could complement or replace existing endotoxin testing workflows.

The solution leverages the natural ability of bacterial outer membrane (OM) proteins to tightly bind small molecules, including lipopolysaccharide (LPS) and its lipid A anchor (endotoxin). By introducing targeted cysteine substitutions and attaching extrinsic fluorophores, the researchers create OM protein constructs whose fluorescence is quenched upon endotoxin binding. This produces a measurable, concentration-dependent signal that enables sensitive detection down to nanomolar levels.

Technical specifications

Core technology:

• Genetically engineered bacterial OM proteins with site-directed cysteine substitutions at endotoxin binding sites
• Covalent attachment of maleimide fluorophores to engineered cysteine residues
• Fluorescence quenching upon endotoxin binding, enabling quantitative detection
• Adaptable to solid-phase assay format visualized by UV or visible light

Development approach:

• Crystallographic analysis identifies precise endotoxin binding sites in OM protein tertiary structures
• Panel of Cys-mutant OM proteins generated and tested for endotoxin binding affinity
• Fluorescence labeling optimized for each mutant variant
• Standardization with purified endotoxin to validate sensitivity and reliability
• Conversion to user-friendly solid-phase format for routine testing

Key advantages:

• Nanomolar sensitivity for endotoxin detection
• Reagent-free design reduces supply chain dependencies
• Potential for clinical, commercial, and field-based sample testing
• Based on a proven platform with over 20 successful fluorescent sensor variants already developed

Technology readiness level

The technology is currently at an early-to-mid stage of development. The research team has established proof of concept through the creation of more than 20 fluorescent sensors for other small molecules using the same OM protein engineering approach, demonstrating the underlying methodology is viable. However, endotoxin-specific sensors have not yet been constructed. The proposed validation plan includes engineering the sensor panel, optimizing fluorescence labeling, validating with purified endotoxin, and converting to solid-phase format. Upon completion of these aims, the technology would advance toward readiness for clinical and commercial validation studies.